New Jersey touts biotech growth

A new survey of New Jersey's biotech industry has found that the drug development business is growing steadily. Combined public and private biotech revenue was set at $5 billion from 238 biotech companies in the state--up from 226 in 2006. And 86 percent of the surveyed companies said they expect to hire 20 or more employees in the next 12 months. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.